Study: Moderna COVID-19 vaccine trial reveals promising immune response in older adults

Researchers say an extension of Moderna’s Phase I trial for its coronavirus vaccine candidate is showing that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects reported as “predominantly mild or moderate in severity.”